HomeInsightsStock Comparison

Sanjivani Paranteral Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Sanjivani Paranteral Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Sanjivani Paranteral Ltd is ₹ 240.3 as of 22 Jul 15:30.
  • The P/E Ratio of Sanjivani Paranteral Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 38.1 on March 2025 . This represents a CAGR of 9.18% over 6 years.
  • The Market Cap of Sanjivani Paranteral Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 416392 crore on March 2025 . This represents a CAGR of 30.45% over 6 years.
  • The revenue of Sanjivani Paranteral Ltd for the Mar '25 is ₹ 18.61 crore as compare to the Dec '24 revenue of ₹ 17.66 crore. This represent the growth of 5.38% The revenue of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 13571 crore as compare to the Dec '24 revenue of ₹ 14141 crore. This represent the decline of -4.03%.
  • The ebitda of Sanjivani Paranteral Ltd for the Mar '25 is ₹ 3.04 crore as compare to the Dec '24 ebitda of ₹ 2.86 crore. This represent the growth of 6.29% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '25 is ₹ 3967 crore as compare to the Dec '24 ebitda of ₹ 4158 crore. This represent the decline of -4.6%.
  • The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.65 crore to ₹ 2.19 crore over 6 quarters. This represents a CAGR of 20.77% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 2160 crore over 8 quarters. This represents a CAGR of 3.60% .
  • The Dividend Payout of Sanjivani Paranteral Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 89.64 % on March 2025 . This represents a CAGR of 20.09% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Sanjivani Paranteral Ltd

  • Sanjivani Paranteral Ltd is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
  • The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a public limited company in Oct.'94, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
  • The Company has been involved in the manufacturing of pharmaceutical medicines.
  • The Company's products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

About Sun Pharmaceutical Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Sanjivani Paranteral Ltd News Hub

News

Board of Sanjivani Paranteral recommends final dividend

Sanjivani Paranteral announced that the Board of Directors of the Company at its meeting h...

Read more

27 May 2025 13:48

News

Sanjivani Paranteral to discuss results

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 27 Ma...

Read more

22 May 2025 19:45

News

Sanjivani Paranteral to discuss results

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 10 Fe...

Read more

31 Jan 2025 10:24

News

Sanjivani Paranteral announces board meeting date

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 28 Oc...

Read more

22 Oct 2024 10:55

News

Sanjivani Paranteral announces board meeting date

Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 9 Sep...

Read more

05 Sep 2024 14:56

News

Sanjivani Paranteral AGM scheduled

Sanjivani Paranteral announced that the 30th Annual General Meeting (AGM) of the company w...

Read more

12 Aug 2024 15:32

Sun Pharmaceutical Industries Ltd News Hub

News

Sun Pharma announces top-line results of tildrakizumab 100 mg Phase 3 studies

Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies...

Read more

21 Jul 2025 09:05

News

Sun Pharmaceutical Industries Ltd spurts 2.56%, rises for third straight session

Sun Pharmaceutical Industries Ltd rose for a third straight session today. The stock is qu...

Read more

15 Jul 2025 13:05

News

Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp

The drug is indicated for the treatment of alopecia areata ' a condition in which the immu...

Read more

15 Jul 2025 15:41

News

Sun Pharmaceutical Industries launches LEQSELVI' (deuruxolitinib) 8 mg tablets in United States

Sun Pharmaceutical Industries announced LEQSELVI' (deuruxolitinib) 8 mg tablets is now ava...

Read more

14 Jul 2025 16:48

News

Sun Pharma settles litigation related to LEQSELVI' with Incyte

 Sun Pharmaceutical Industries  announced that further to its intimation dated 10 April 20...

Read more

14 Jul 2025 16:53

News

Sun Pharmaceuticals Industries to table results

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Compan...

Read more

12 Jul 2025 10:08

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Sanjivani Paranteral Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Sun Pharmaceutical Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Sanjivani Paranteral Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Sanjivani Paranteral Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Sanjivani Paranteral Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Sanjivani Paranteral Ltd is 286 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 405,871 Cr

What are the key factors driving the stock performance of Sanjivani Paranteral Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Sanjivani Paranteral Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanjivani Paranteral Ltd and Sun Pharmaceutical Industries Ltd?

As of July 22, 2025, the Sanjivani Paranteral Ltd stock price is INR ₹236.95. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1691.6.

How do dividend payouts of Sanjivani Paranteral Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Sanjivani Paranteral Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions